|
20 Apr 2020 |
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
|
|
20 Apr 2020 |
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin® Proteins to Neutralize SARS-CoV-2 Virus
|
|
10 Apr 2020 |
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
|
|
08 Apr 2020 |
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
|
|
04 Apr 2020 |
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
|
|
02 Apr 2020 |
Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment
|
|
02 Apr 2020 |
Synairgen confirms commencement of dosing in trial of SNG001 in COVID-19
|
|
02 Apr 2020 |
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
|
|
02 Apr 2020 |
APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
|
|
01 Apr 2020 |
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
|
|
01 Apr 2020 |
Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease
|
|
30 Mar 2020 |
Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery
|
|
26 Mar 2020 |
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
|
|
22 Mar 2020 |
Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim
|
|
18 Mar 2020 |
Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
|
|
18 Mar 2020 |
Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer
|
|
16 Mar 2020 |
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
|
|
11 Mar 2020 |
Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus
|
|
11 Mar 2020 |
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist
|
|
03 Mar 2020 |
Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
|
|
26 Feb 2020 |
Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial
|
|
26 Feb 2020 |
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China
|
|
25 Feb 2020 |
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and
|
|
24 Feb 2020 |
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
|
|
21 Feb 2020 |
NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke
|
